AstraZeneca Results Presentation Deck
BioPharmaceuticals: Cardiovascular, Renal and Metabolism
Total Revenue $8.0bn; growth +9%
Farxiga: 49% growth to $3.0bn
Strong momentum continues, fastest growing SGLT2i globally
22
$m
900
800
700
600
500
400
300
200
100
0
Q4
2019
Q1
Q2
Q3 Q4
2020
US Europe EROW EM
Q1
Q2
Q3 Q4
2021
US +29%, Europe +52% and EM
+70%, boosted by HFrEF and CKD
launches
• Volumes growing faster than the
SGLT2i market in most major
markets
China NRDL status renewed
• #1 innovative anti-diabetic
in China and Brazil
Now
blockbuster
status in
EM
US branded K+ binder TRX share¹
●
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Jul-19
Lokelma
Global sales of $175m
Sep-19
Jan-20
Nov-19
Mar-20
May-20
Jul-20
Sep-20
Nov-20
SGLT2i = sodium-glucose transport protein 2 inhibitor; HFrEF = heart failure with reduced ejection fraction; CKD = chronic kidney disease; K+ = potassium; TRx = total prescriptions. 1. IQVIA US monthly total prescription share data
Jan-21
Mar-21
Jul-21
May-21
Sep-21
Nov-21
Lokelma Branded competitor
Continued strong growth in US and
Japan. Expanding in new markets in
Europe with new reimbursements
achieved
China NRDL listing from January 2022
61%View entire presentation